Stephens Inc. AR Acquires 17,286 Shares of Medtronic PLC $MDT

Stephens Inc. AR lifted its holdings in shares of Medtronic PLC (NYSE:MDT) by 6.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 284,904 shares of the medical technology company’s stock after acquiring an additional 17,286 shares during the quarter. Stephens Inc. AR’s holdings in Medtronic were worth $24,815,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of MDT. CSM Advisors LLC grew its position in Medtronic by 13.2% in the third quarter. CSM Advisors LLC now owns 285,260 shares of the medical technology company’s stock worth $27,169,000 after acquiring an additional 33,167 shares in the last quarter. SageView Advisory Group LLC lifted its position in Medtronic by 164.8% in the 3rd quarter. SageView Advisory Group LLC now owns 24,204 shares of the medical technology company’s stock worth $2,305,000 after buying an additional 15,062 shares during the last quarter. Madison Asset Management LLC boosted its stake in Medtronic by 15.0% in the fourth quarter. Madison Asset Management LLC now owns 195,216 shares of the medical technology company’s stock worth $18,752,000 after buying an additional 25,527 shares in the last quarter. Ticino Wealth purchased a new stake in Medtronic in the fourth quarter worth approximately $2,049,000. Finally, First Eagle Investment Management LLC grew its position in Medtronic by 0.4% during the fourth quarter. First Eagle Investment Management LLC now owns 9,775,234 shares of the medical technology company’s stock valued at $939,009,000 after acquiring an additional 40,196 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Investors continue to reward Medtronic’s stronger-than-expected fiscal Q4 results and improved fiscal 2027 outlook, which included solid revenue growth and guidance that supports a more constructive growth narrative for the stock.
• Positive Sentiment: Medtronic expanded its partnership with Retia Medical to distribute the Argos cardiac output monitor more broadly, supporting growth in high-acuity cardiovascular and critical-care markets and reinforcing the company’s expansion into higher-growth device categories. Article Title
• Positive Sentiment: Analyst sentiment remains favorable, with recent coverage showing a “Moderate Buy” tone and several firms maintaining bullish ratings, which may be helping support the share price. Article Title
• Neutral Sentiment: Articles discussing why MDT is up since its last earnings report suggest the move may be a continuation of post-earnings buying rather than a reaction to a fresh catalyst, indicating momentum more than a new surprise. Article Title
• Neutral Sentiment: Medtronic has begun notifying people affected by a cyberattack, but the company said there is no evidence the accessed data was posted online and no impact to patient safety or core operations has been identified so far. Article Title
• Negative Sentiment: The cybersecurity incident still introduces headline risk and potential reputational or legal concerns, even though Medtronic says the event has not affected operations.

Medtronic Price Performance

Shares of MDT stock opened at $83.07 on Monday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.62 and a current ratio of 2.13. Medtronic PLC has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The firm has a market cap of $106.33 billion, a P/E ratio of 22.27, a P/E/G ratio of 2.23 and a beta of 0.56. The business’s 50 day moving average price is $79.04 and its 200-day moving average price is $89.00.

Medtronic (NYSE:MDT) last announced its earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The company had revenue of $9.81 billion during the quarter, compared to the consensus estimate of $9.62 billion. During the same quarter in the prior year, the company earned $1.62 earnings per share. The firm’s revenue for the quarter was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, equities research analysts anticipate that Medtronic PLC will post 5.94 earnings per share for the current year.

Medtronic Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 17th. Shareholders of record on Friday, June 26th will be issued a $0.72 dividend. This is a boost from Medtronic’s previous quarterly dividend of $0.71. The ex-dividend date is Friday, June 26th. This represents a $2.88 annualized dividend and a yield of 3.5%. Medtronic’s dividend payout ratio (DPR) is currently 77.21%.

Analyst Upgrades and Downgrades

Several research analysts have commented on MDT shares. Argus decreased their price target on shares of Medtronic from $125.00 to $115.00 and set a “buy” rating on the stock in a research note on Monday, April 6th. Mizuho decreased their target price on shares of Medtronic from $120.00 to $100.00 and set an “outperform” rating on the stock in a research report on Wednesday, June 3rd. Robert W. Baird lowered their price target on shares of Medtronic from $93.00 to $85.00 and set a “neutral” rating for the company in a research note on Thursday, June 4th. Sanford C. Bernstein reduced their price objective on Medtronic from $112.00 to $97.00 and set an “outperform” rating on the stock in a research note on Thursday, June 4th. Finally, Stifel Nicolaus set a $80.00 target price on Medtronic in a research note on Wednesday, June 3rd. Seventeen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $99.00.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 4,189 shares of the firm’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the sale, the executive vice president directly owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. This trade represents a 10.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.26% of the company’s stock.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).